Overview

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
Phase:
PHASE2
Details
Lead Sponsor:
Alnylam Pharmaceuticals